Ascentage Pharma

Ascentage Pharma Group International is a globally focused, clinical-stage biopharmaceutical company dedicated to developing innovative therapies for the treatment of cancer, hepatitis B virus (HBV), and age-related diseases. Leveraging its expertise in structure-based drug design and innovative drug discovery engines, the company has developed seven drug candidates currently in clinical stages. The company’s portfolio includes novel small-molecule drug candidates capable of disrupting complex and difficult-to-target protein-protein interactions (PPIs) and next-generation tyrosine kinase inhibitors (TKIs). The company's PPI drug candidates can treat cancer and other diseases by restoring the normal function of key intrinsic apoptosis pathways such as Bcl-2/Bcl-xL, MDM2-p53, and IAP pathways, which play critical roles in regulating apoptosis. The company is also developing multiple next-generation TKIs to address diseases with significant unmet medical needs. Currently, the company is researching compounds that can be used alone or in combination with other therapies. Ascentage Pharma is conducting 20 Phase I or II clinical trials in the United States, Australia, and China to evaluate its seven drug candidates. Additionally, by developing and implementing biomarker strategies within its drug discovery programs, the company aims to enhance the success rates of its clinical trials.